Needle-Free Delivery Technology Market - Forecasts from 2021 to 2026

The needle-free delivery technology market is projected to grow at a CAGR of 5.24% to reach US$14.093 billion by 2026, from US$9.857 billion in 2019. Needle-free drug delivery systems are an innovative method of drug delivery and other types of medicines. These can be in the form of transdermal patches, inhaling systems, or even micro-needles that do not pierce the skin like conventional needles. This technology is beneficial over conventional delivery technologies as it reduces patient's concerns regarding the use of needles. It has certain additional benefits over the conventional ones such as fast delivery and no issues related to needle disposal. These needle-free devices are available in reusable and disposable forms and are also available in the form of multiple patient uses. The advancements in technology and investments in the field of pain-free drug transportation and self-administration are driving the growth of the global needle-free delivery technology market in the forecast period. For instance, Zogenix introduced DosePro, a needle-free medication transportation technology, which is a prefilled, single-use, disposable subcutaneous medicine transportation system for self-administration of liquid medicine formulations in 2015.

In addition, the prevalence of diseases worldwide will provide an opportunity for the development of novel drug delivery technologies providing an opportunity for the growth of needle-free delivery technologies in the coming years. The increasing incidence of infectious diseases such as hepatitis, dengue fever, neurological disorders, and AIDS will further fuel the market demand for needle-free technology, globally. According to the Global HIV Statistics, 2020, there were approximately 37.6 million people across the globe with HIV in 2020. Of these, 35.9 million were adults and 1.7 million were children, these increasing numbers could be attributed to injection drug use (IDU). Moreover, the changing lifestyles patterns have led to an increase in the number of diabetic patients worldwide which will fuel the market growth as diabetic patients are the primary target audience for this technology. According to the International Diabetes Federation, 2019, approximately 463 million adults (20-79 years) were living with diabetes, the number is expected to rise to 700 million by 2045, which will contribute to the market growth.

Furthermore, the key market players are investing in needle-free drug delivery technology to meet the increasing consumer demand which will, in turn, strengthen the market growth during the forecast period. For instance, in January 2020, LEO Pharma A/S and Portal Instruments are collaborated and forged a license agreement to develop Portal’s needle-free drug delivery system for use in combination with LEO Pharma’s portfolio of investigational and approved medicines. Also, in October 2018, Frost & Sullivan recognized PharmaJet with the 2018 Global Technology Innovation Award for an innovative jet injection technology that offered a needle-free, accurate, and consistent method of vaccine delivery.

By type, the liquid injections segment is expected to hold a dominant market share owing to the advantages of this mode of delivery over the other methods. Geographically, North America is estimated to witness significant market growth on account of the increasing number of diabetic patients in the region, the early adoption, and raising awareness of this technology amongst the users. Also, the Asia Pacific region is anticipated to grow at a high CAGR due to the increasing incidence of diabetes in the region.

Growth Factors

Increasing diabetic patients

The constant surge in the number of diabetic patients worldwide is expected to contribute majorly towards the market growth of the needle-free delivery technology market during the next few years. According to the International Diabetes Federation, 1 in 5 people who are above 65 years old has diabetes. Also, more than 1.1 million children and adolescents are living with type 1 diabetes, worldwide. The rise in the number of diabetic patients will increase the demand and adoption of needle-free delivery technology which will drive the market growth during the forecast period.

Restraints

High costs

The major restraint for the needle-free delivery technology market is the high costs associated with this technology. The needle-free delivery technology is much costlier than the conventional needles which may restrain the market growth in the long run as the majority of the population, especially in developing countries might not be able to afford this technology.

Impact Of COVID–19 On The Needle-Free Delivery Technology Market.

The Covid-19 pandemic moderately impacted the needle-free delivery technology market as due to the nationwide lockdown restrictions, many patients deferred their ongoing treatments and postponed their diagnosis to avoid public places which hampered the market growth. However, the existing diabetic patients did use the needle-free delivery technology as a part of their treatment which balanced the market growth during the novel pandemic.

Competitive Insights

The market leaders for the needle-free delivery technology market consist of 3M Company, Antares Pharma, Inc., Penjet Corporation, National Medical Products, Inc., AcuShot™ Inc., Crossject SA, INJEX Pharma GmbH, Aradigm Corporation, Transdermal Specialties Inc., UCB S.A., Belgium, and Vaxxas, Inc.

Segmentation:

By Type

• Powder Injection
• Liquid Injection
• Depot Injection

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• UK
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• Indonesia
• Taiwan
• Thailand
• Others